Healthcare / BiotechnologyNasdaqCM
$24.07
+2.17 (+9.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-36.4M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$97M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-100.6%
↓Gross Margin
N/A
•Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-79.6%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $27.5M · net income $-26.6M · FCF $-21.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $27.5M | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.2M | $3.5M | $1.1M | — |
| Net Income | $-26.6M | $-26.6M | $-40.7M | $-50.7M | $-53.0M | $-44.2M | $-44.8M | $-36.7M | $-39.0M | $-23.2M |
| EBITDA | $-22.3M | $-22.3M | $-37.5M | $-46.1M | $-50.5M | $-42.5M | $-44.0M | $-36.0M | $-37.9M | — |
| EPS | -8.40 | -8.40 | -21.60 | -33.30 | -44.70 | -42.30 | — | — | — | — |
| Operating Margin | -96.6% | -96.6% | -447.9% | -947.0% | -4297.3% | -292.6% | -1428.0% | -1063.2% | -3386.7% | — |
| Net Margin | -96.9% | -96.9% | -438.0% | -924.1% | -4257.8% | -295.6% | -1419.8% | -1061.2% | -3411.5% | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.16 | 0.16 | 0.51 | 0.40 | 0.29 | 0.00 | — | — | — | — |
| Current Ratio | 3.57 | 3.57 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-21.9M | $-21.9M | $-36.4M | $-40.0M | $-42.0M | $-39.8M | $-33.1M | $-30.8M | $-28.3M | $-13.2M |
| Returns | ||||||||||
| ROE | -100.6% | -100.6% | -232.4% | -136.8% | -80.7% | -67.4% | -56.8% | -67.2% | -114.7% | -37.7% |
| Valuation | ||||||||||
| P/B | 2.87 | 2.87 | 4.47 | 3.23 | 1.54 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 195.7% | 195.7% | 69.2% | 341.0% | — | 373.7% | -8.8% | 202.7% | — | — |
| EPS Growth | 61.1% | 61.1% | 35.1% | 25.5% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-21.60 → -8.40
Residual
+25.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.